Bevacizumab: A Review of Its Use in Advanced Cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
http://link.springer.com/article/10.1007/s40265-014-0302-9/fulltext.html
Reference241 articles.
1. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs. 1995;6(1):3–18.
2. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004;9(Suppl 1):2–10.
3. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581–611.
4. Ferrara N, Hillan KJ, Gerber H-P, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.
5. European Medicines Agency. Avastin (bevacizumab): EPAR procedural steps taken before authorisation. 2006. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000582/human_med_000663.jsp&mid=WC0b01ac058001d124 . Accessed 17 Sep 2014.
Cited by 138 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A patent perspective of antiangiogenic agents;Expert Opinion on Therapeutic Patents;2023-12-02
2. Anti-angiogenic and oxidative effects of sodium benzoate at different concentrations in chorioallantoic membrane model;Journal of Clinical and Experimental Investigations;2023-11-11
3. Anti-angiogenic and oxidative effects of brilliant blue at different concentrations in chorioallantoic membrane model;Journal of Contemporary Studies in Epidemiology and Public Health;2023-09-20
4. Corneal Perforation in a Patient Treated with Atezolizumab-Bevacizumab Combination Therapy for Unresectable Hepatocellular Carcinoma;American Journal of Case Reports;2023-07-18
5. A comprehensive review on lipid nanocarrier systems for cancer treatment: fabrication, future prospects and clinical trials;Journal of Liposome Research;2023-05-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3